Working… Menu
Trial record 1 of 1 for:    Hu5F9-G4 avelumab
Previous Study | Return to List | Next Study

Trial of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03558139
Recruitment Status : Completed
First Posted : June 15, 2018
Last Update Posted : July 27, 2021
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
Gilead Sciences

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 3, 2020
Actual Study Completion Date : December 3, 2020